Trial · NCT04280081
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1 | Complete Response | 3.8 | 95% Confidence Interval 0.1 to 19.6 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Fusion Positive Thyroid Cancer (TC) Cohort 1 | Complete Response | 0 | 95% Confidence Interval 0.0 to 97.5 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2 | Complete Response | 7.7 | 95% Confidence Interval 0.9 to 25.1 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1 | Partial Response | 65.4 | 95% Confidence Interval 44.3 to 82.8 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Fusion Positive Thyroid Cancer (TC) Cohort 1 | Partial Response | 100.0 | 95% Confidence Interval 2.5 to 100.0 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2 | Partial Response | 50.0 | 95% Confidence Interval 29.9 to 70.1 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1 | Overall Response (CR/PR) | 69.2 | 95% Confidence Interval 48.2 to 85.7 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Fusion Positive Thyroid Cancer (TC) Cohort 1 | Overall Response (CR/PR) | 100.0 | 95% Confidence Interval 2.5 to 100.0 | percentage of participants |
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2 | Overall Response (CR/PR) | 57.7 | 95% Confidence Interval 36.9 to 76.6 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Non-small Cell Lung Cancer (All NSCLC) | Complete Response | 6.4 | 95% Confidence Interval 1.3 to 17.5 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Thyroid Cancer (All TC) | Complete Response | 0 | 95% Confidence Interval 0.0 to 97.5 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Medullary Thyroid Cancer (All MTC) | Complete Response | 10.3 | 95% Confidence Interval 2.2 to 27.4 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Non-small Cell Lung Cancer (All NSCLC) | Partial Response | 59.6 | 95% Confidence Interval 44.3 to 73.6 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Thyroid Cancer (All TC) | Partial Response | 100.0 | 95% Confidence Interval 2.5 to 100.0 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Medullary Thyroid Cancer (All MTC) | Partial Response | 48.3 | 95% Confidence Interval 29.4 to 67.5 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Non-small Cell Lung Cancer (All NSCLC) | Overall Response (CR/PR) | 66.0 | 95% Confidence Interval 50.7 to 79.1 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Thyroid Cancer (All TC) | Overall Response (CR/PR) | 100.0 | 95% Confidence Interval 2.5 to 100.0 | percentage of participants |
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC | Medullary Thyroid Cancer (All MTC) | Overall Response (CR/PR) | 58.6 | 95% Confidence Interval 38.9 to 76.5 | percentage of participants |
| Enrolled Population: Duration of Response (DoR) as Assessed by IRC | All NSCLC | NA | 95% Confidence Interval NA to NA | months | |
| Enrolled Population: Duration of Response (DoR) as Assessed by IRC | All TC | NA | 95% Confidence Interval NA to NA | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04280081/results